Sustained Vd1 and Vd2 T-cell profiles in chronic viral hepatitis

2016 ◽  
Vol 54 (12) ◽  
pp. 1343-1404
Author(s):  
B Binder ◽  
A Schuch ◽  
B van Wilgenburg ◽  
A Hoh ◽  
P Klenerman ◽  
...  
1991 ◽  
Vol 12 (2) ◽  
pp. 190-194 ◽  
Author(s):  
E.L. Krawitt ◽  
A. Zannier ◽  
P. Chossegros ◽  
F. Gerard ◽  
M. Chevallier ◽  
...  

Cytotherapy ◽  
2017 ◽  
Vol 19 (11) ◽  
pp. 1317-1324 ◽  
Author(s):  
Antonio Bertoletti ◽  
Anthony Tanoto Tan ◽  
Sarene Koh

2017 ◽  
Vol 35 (4) ◽  
pp. 334-338 ◽  
Author(s):  
Dominik Wieland ◽  
Maike Hofmann ◽  
Robert Thimme

About 500 million people all over the world are chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) and are thus at high risk of developing liver fibrosis, cirrhosis or hepatocellular carcinoma. While in adults about 90% of acutely HBV-infected patients clear the virus, only 30% of acute HCV infections clear spontaneously. Several mechanisms contribute to the failure in viral clearance. The main factors responsible for the chronification of HBV and HCV infection are, on the one hand, viral escape mutations leading to lack of recognition by antiviral immune cells and, on the other hand, loss of antiviral effector functions of virus-specific CD8+ T cells, called T-cell exhaustion. This review focuses on the latter highlighting current knowledge about the heterogeneity of exhausted CD8+ T cells and the potential for re-invigoration of exhausted T-cell populations during chronic viral hepatitis. Although direct-acting antivirals successfully clear chronic HCV infection, there is still the need for a prophylactic vaccine to prevent primary infection. Moreover, a therapeutic strategy eliminating HBV infection still does not exist. A better understanding of T-cell exhaustion and the potential for functional recovery will help to develop new immunotherapeutic approaches for chronic viral hepatitis.


2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Pascal Lapierre ◽  
Alain Lamarre

In both autoimmune liver disease and chronic viral hepatitis, the injury results from an immune-mediated cytotoxic T cell response to liver cells. As such, it is not surprising that CD4+regulatory T cells, a key regulatory population of T cells able to curb immune responses, could be involved in both autoimmune hepatitis and chronic viral hepatitis. The liver can induce the conversion of naïve CD4+T cells to CD4+regulatory T cells and induce tolerance to locally expressed antigens. This tolerance mechanism is carefully regulated in physiological conditions but any imbalance could be pathological. An overly tolerant immune response can lead to chronic infections while an overreactive and unbridled immune response can lead to autoimmune hepatitis. With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.  


2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Franklin S. Azebaze Agueguia ◽  
Paul Talla ◽  
Marie C. Okomo Assoumou ◽  
Graeme B. Jacobs ◽  
Cedric H. Mbakam ◽  
...  

2002 ◽  
Vol 123 (6) ◽  
pp. 2154-2155
Author(s):  
Satheesh Nair

2020 ◽  
Vol 18 (7) ◽  
Author(s):  
Tatiana Ghelimici ◽  
Iulianna Lupasco ◽  
Vlada-Tatiana Dumbrava ◽  
Inna Vengher ◽  
Natalia Taran ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document